Botulinum toxin injection of the lower esophageal sphincter to identify achalasia-variant esophagogastric junction outflow obstruction
Diseases of the Esophagus · 2025
DOI: 10.1093/dote/doae082 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Chanakyaram A Reddy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Esophageal Diseases, Baylor University Medical Center, Department of Internal Medicine, Division of Gastroenterology, Dallas, TX, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Diagnostic Techniques, Digestive System, Esophageal Achalasia, Esophagogastric Junction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Esophagogastric junction outflow obstruction (EGJOO) can be an achalasia variant caused by neuromuscular dysfunction of the lower esophageal sphincter (LES), or the manometric manifestation of mechanical processes that impair EGJ distensibility. Distinction among these conditions has important implications for treatment, but can be difficult. We hypothesized that response to botulinum toxin (BT) injection of the LES could be a diagnostic test for identifying achalasia-variant EGJOO likely to respond to LES muscle-directed invasive therapy. We reviewed our experience with symptomatic EGJOO patients who had BT injection of the LES. Data collected include demographics, esophageal body manometry findings, esophagram evidence of retention, and symptom response at 1–6 months after BT injection categorized as poor, partial, or good. Clinical response to any subsequent LES-directed invasive treatment (EsoFLIP dilation, pneumatic dilation, Heller myotomy, or POEM) also was recorded. Thirteen symptomatic EGJOO patients were included (mean age 55.9 ± 16.4 years; eight men, five women). Symptom response to BT injection was good in six (46%), partial in three (23%), and poor in three (23%); one was lost to follow-up. All five patients who received invasive treatment after partial or good response to BT had a partial or good response to invasive treatment. The one patient who had invasive treatment after a poor response to BT had a poor response to invasive treatment. These findings suggest that a good response to BT injection of the LES can identify an achalasia-variant form of EGJOO that will respond to LES muscle-directed invasive therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Esophageal Diseases, Baylor University Medical Center, Department of Internal Medicine, Division of Gastroenterology, Dallas, TX, USA.
- Center for Thoracic Surgery, Baylor University Medical Center, Department of Surgery, Dallas, TX, USA.
ORCID-Profile: Chanakyaram A Reddy
Zitieren
APA
Reddy, C. A., Ellison, A., Nguyen, A. D., Podgaetz, E., Souza, R. F., Konda, V. J. A., & Spechler, S. J. (2025). Botulinum toxin injection of the lower esophageal sphincter to identify achalasia-variant esophagogastric junction outflow obstruction. Diseases of the Esophagus. https://doi.org/10.1093/dote/doae082
Vancouver
Reddy CA, Ellison A, Nguyen AD, Podgaetz E, Souza RF, Konda VJA, et al. Botulinum toxin injection of the lower esophageal sphincter to identify achalasia-variant esophagogastric junction outflow obstruction. Diseases of the Esophagus. 2025. doi:10.1093/dote/doae082
BibTeX
@article{Reddy2025,
author = {Reddy, Chanakyaram A and Ellison, Ashton and Nguyen, Anh D and Podgaetz, Eitan and Souza, Rhonda F and Konda, Vani J A and Spechler, Stuart J},
title = {Botulinum toxin injection of the lower esophageal sphincter to identify achalasia-variant esophagogastric junction outflow obstruction},
journal = {Diseases of the Esophagus},
year = {2025},
doi = {10.1093/dote/doae082}
}
EUVIMED